IBALIZUMAB-UIYK (TROGARZO®) PRESCRIBER ORDER FORM							
Fax completed form, insurance information, and clinical documentation to: (888) 410-2584							
∼ INTELLIGENT	Patient Name:				Date of Birth:		
HEALTH COMPANY.	Address:						
UBACARE	Phone:		Height:	☐ inches ☐	cm Weight:	☐ Ibs ☐ kg	
		Clinica	al Information				
Primary Diagnosis Description: Human immunodeficiency virus (HIV							
Is this the first dose? ☐ Yes – date of first dose:			☐ No – date of next dose due:				
Ibalizumab-uiyk (Trogarzo®) 200 mg/1.33 mL vials refill as directed x 1 year Loading Dose:							
Anaphylaxis Kit If this is a 1 st dose, would you like Option Care to provide an anaphylaxis kit with the 1 st dose? □ Yes – please complete Anaphylaxis Physician Order (FR-PC-036) Medication Orders □ Other:							
IV Flush Orders Peripheral Peripheral	-Midline: NS 3 to 5 mL pre-/post-use, 5 mL pre-lab draw, and 10 mL post-lab draw. Heparin (100 unit/mL) 3 mL post-use. For maintenance, flush with heparin (100						
□ PICC and C	entral Tunneled/Non-Tunneled	unit/mL) 3 mL every 24 hr. MS 5 mL pre-/post-use, 5 mL pre-lab draw, and 10 mL post-lab draw. Heparin □ (10 unit/mL) 5 mL <u>or</u> □ (100 unit/mL) 3 mL post-use. For maintenance, flush with heparin (10 unit/mL) 5 mL or (100 unit/mL) 3 mL every 24 hr. NS 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3					
to 5 mL every 24 hr if accessed or weekly to monthly if not accessed. Lab Orders No labs ordered at this time.							
☐ Other: Skilled nurse to administer doses intravenously. Refill above ancillary orders as directed x 1 year. I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment.							
Prescriber Signature:	Date: er Information						
Prescriber Name:			Phone:		Fax:		
Address:			NPI:				
City, State:		Zip:	Office Contact:				

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is need to the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.